Logo

SABSW

SAB Biotherapeutics, Inc.

SABSW

SAB Biotherapeutics, Inc. • NASDAQ
$0.02 ▼ -25.93% (-0.01)
Market Cap $210280
52w High $0.05
52w Low $0.02
Dividend Yield 0%
P/E 0.08
Volume 143.18K
Outstanding Shares 9.56M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $11.914M ▲ $5.338M ▲ 0% $0.5 ▲ $46.254M ▲
Q2-2025 $0 $8.91M ▼ $-10.114M ▼ 0% $-1.09 ▼ $-9.228M ▼
Q1-2025 $0 ▼ $9.994M ▲ $-5.197M ▲ 0% ▲ $-0.56 ▲ $-4.349M ▲
Q4-2024 $114.698K ▲ $9.338M ▼ $-11.395M ▼ -9.935K% ▼ $-1.23 ▼ $-10.538M ▼
Q3-2024 $0 $10.343M $-10.349M 0% $-1.12 $-9.305M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $110.881M ▲ $183.448M ▲ $18.374M ▲ $165.074M ▲
Q2-2025 $5.714M ▼ $30.129M ▼ $18.113M ▲ $12.016M ▼
Q1-2025 $12.85M ▼ $38.12M ▼ $16.713M ▼ $21.407M ▼
Q4-2024 $20.761M ▼ $44.195M ▼ $18.226M ▲ $25.97M ▼
Q3-2024 $30.401M $53.797M $16.895M $36.903M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $5.338M ▲ $-13.05M ▼ $-129.869M ▼ $168.689M ▲ $25.732M ▲ $-13.05M ▼
Q2-2025 $-10.114M ▼ $-7.152M ▲ $5.198M ▲ $-173.844K ▲ $-1.948M ▲ $-7.152M ▲
Q1-2025 $-5.197M ▲ $-7.797M ▲ $4.671M ▼ $-173.985K ▼ $-3.258M ▼ $-7.797M ▲
Q4-2024 $-11.395M ▼ $-9.271M ▼ $9.331M ▲ $-44.144K ▲ $-273.209K ▲ $-9.326M ▼
Q3-2024 $-10.349M $-6.292M $-1.153M $-674.13K $-8.071M $-6.392M

Five-Year Company Overview

Income Statement

Income Statement SAB Biotherapeutics is still essentially a pre‑revenue company. Recent years show almost no meaningful sales and consistent operating losses as research, clinical trials, and overhead outweigh any small income streams. Profitability briefly appeared earlier in the period but has not been sustained. Overall, the business is still in the investment and development phase rather than the earnings phase, which is typical for a clinical‑stage biotech but means results depend heavily on future trial success and partnerships, not current operations.

Balance Sheet

Balance Sheet The balance sheet is small and reflects an early‑stage biotech: modest total assets, a limited but important cash buffer, and very little debt. Equity remains positive, which is a plus, but the financial base is thin, so the company is more exposed to swings in funding conditions or setbacks in its programs. The low debt load reduces interest pressure but also highlights reliance on equity raises, grants, or partners to support development.

Cash Flow

Cash Flow Cash flow is negative from core operations, which means the company is consistently using cash to fund research and trials rather than generating cash from product sales. Capital spending is minimal, so most outflows are tied directly to running the business and advancing the pipeline. Free cash flow has been negative, underlining a continuing need for external financing. The referenced private financing improves the runway, but long‑term sustainability still depends on successful trial milestones and future funding access.

Competitive Edge

Competitive Edge SAB’s competitive position is built around a unique polyclonal antibody platform using genetically engineered cattle to produce fully human antibodies. This could offer advantages over traditional monoclonal antibodies, especially for fast‑mutating viruses and complex immune diseases. The company has validation through government collaborations and a few strategic partners, but it is still small compared with major pharmaceutical players. Its moat depends on continued proof that the platform works better or faster than alternatives, plus the ability to convert that edge into approved products and commercial deals before larger competitors close the gap.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here. The DiversitAb platform and transchromosomic cattle approach are unusual and scientifically ambitious. The lead program in type 1 diabetes targets disease modification, not just symptom control, which, if proven, would be a major step forward. The influenza candidate and preclinical programs show the platform can be applied in multiple areas. At the same time, most value is still in the lab and in early‑ to mid‑stage trials, so scientific and regulatory risk is high: setbacks in a few key studies would materially change the outlook.

Summary

Overall, SAB Biotherapeutics is a classic early‑stage biotech story: strong emphasis on novel science, minimal current revenue, continuing losses, and dependence on external funding. The technology and pipeline suggest meaningful upside potential if clinical data continue to be favorable, particularly in type 1 diabetes and influenza. On the other hand, the small balance sheet, ongoing cash burn, and concentration in a few flagship programs create significant execution and financing risk. Future trial results, partnering activity, and cash runway developments will likely matter far more than recent historical financials in shaping the company’s trajectory.